A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Ann Oncol
; 30(8): 1279-1288, 2019 08 01.
Article
in En
| MEDLINE
| ID: mdl-31095287
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Biomarkers, Tumor
/
Neoadjuvant Therapy
/
Triple Negative Breast Neoplasms
/
Antibodies, Monoclonal
Type of study:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2019
Type:
Article